MAIA Biotechnology Files 8-K

Ticker: MAIA · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1878313

Sentiment: neutral

Topics: sec-filing, corporate-update, pharmaceutical

TL;DR

MAIA Bio filed an 8-K on 9/12/25, expect updates.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on September 12, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Chicago, IL, operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates MAIA Biotechnology, Inc. is providing updates on its corporate activities and financial status to the SEC.

Risk Assessment

Risk Level: low — This is a routine filing for corporate updates and does not inherently signal significant risk.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by MAIA Biotechnology, Inc. in this 8-K filing?

The filing indicates 'Other Events' as an item, but the specific details of these events are not provided in the excerpt.

What is the SIC code for MAIA Biotechnology, Inc.?

The Standard Industrial Classification (SIC) code for MAIA Biotechnology, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

When was MAIA Biotechnology, Inc. incorporated?

MAIA Biotechnology, Inc. was incorporated in Delaware.

What is the business address and phone number for MAIA Biotechnology, Inc.?

The business address is 444 West Lake Street, Suite 1700, Chicago, IL 60606, and the phone number is (312) 416-8592.

Does this 8-K filing relate to any specific financial statements or exhibits?

Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item information category.

Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-09-12 16:05:49

Filing Documents

01 Other Events

Item 8.01 Other Events On September 12, 2025, MAIA Biotechnology, Inc. (the "Company") posted an updated presentation about the Company's business on its website ( www.maiabiotech.com ), a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K ("Report") and is hereby incorporated by reference. The information contained in the presentation is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. The presentation speaks as of the date of this Report. While the Company may elect to update the presentation in the future to reflect events and circumstances occurring or existing after the date of this Report, the Company specifically disclaims any obligation to do so. The presentation contains forward-looking statements, and as a result, investors should not place undue reliance on these forward-looking Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 12, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing